CAS 183319-69-9

Cloridrato de erlotinibe

Descrição:

Cloridrato de erlotinibe é um inibidor de tirosina quinase de pequenas moléculas usado principalmente no tratamento do câncer de pulmão de células não pequenas e câncer de pâncreas. Ele visa especificamente o receptor do fator de crescimento epidérmico (EGFR), inibindo sua atividade e bloqueando assim as vias de sinalização que promovem o crescimento e a sobrevivência do tumor. O composto é tipicamente administrado por via oral e é conhecido por sua capacidade de penetrar a barreira hematoencefálica, tornando-o eficaz para certas metástases cerebrais. Cloridrato de erlotinibe é caracterizado por sua solubilidade em água devido à presença do sal de cloridrato, que melhora sua biodisponibilidade. A fórmula molecular reflete sua estrutura complexa, que inclui um núcleo de quinazolina. Os efeitos colaterais comuns associados ao seu uso incluem erupção cutânea, diarreia e possível elevação das enzimas hepáticas. Assim como em muitas terapias direcionadas, a eficácia do erlotinibe pode ser influenciada pela presença de mutações específicas no gene EGFR, tornando o teste genético uma consideração importante no planejamento do tratamento. No geral, Cloridrato de erlotinibe representa um avanço significativo na terapia personalizada contra o câncer.

Fórmula: C₂₂H₂₄ClN₃O₄

InChI: InChI=1/C22H23N3O4.ClH/c1-4-16-5-7-17(8-6-16)25-22-18-13-20(28-11-9-26-2)21(29-12-10-27-3)14-19(18)23-15-24-22;/h1,5-8,13-15H,9-12H2,2-3H3,(H,23,24,25);1H

Chave InChI: InChIKey=GTTBEUCJPZQMDZ-UHFFFAOYSA-N

SMILES: N(C=1C2=C(C=C(OCCOC)C(OCCOC)=C2)N=CN1)C3=CC(C#C)=CC=C3.Cl

Sinónimos:

• 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, hydrochloride (1:1)
• 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride
• 6,7-Bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline hydrochloride
• Cp 358774
• Erlotinib HCl
• Erlotinib Hcl Salt
• Erlotinib, Hydrochloride Salt
• Erlotinib, OS-774
• N-(2-chloro-6-methyl-phenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-pyrimidin-4-yl]amino]thiazole-5-carboxamide
• N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4- Hydrochloride
• N-(3-Ethynylphenyl)-6,7-bis-(2-methoxyethoxy)-quinazolin-4-amine Hydrochloride
• N-(3-Ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine hydrochloride
• N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
• N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride (1:1)
• N-(4-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride (1:1)
• Osi 774
• Tarceva
• [6,7-Bis(2-methoxyethoxy)quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride
• [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4yl]-(3-ethynyl-phenyl)-amine
• quinazolinamine, Hydrochloride Salt, OSI 774, Tarceva
• Tarceva Hydrochloride See E625000
• Erlotinib HCl(TINIBS)
• Erlotinib hydrochloride
• ERLOTINIB
• 6,7-BIS(2-METHOXYETHOXY)-4-(3-ETHYNYLANILINO)QUINAZOLINE HCL
• ERLOTINIB HCL SALT :TARCEVA
• erlotinib hydorchloride
• N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, Hydrochloride Salt, OSI 774, Tarceva
• 21 Erlotinib hydrochloride and Intermediate
• Tarceva HydrochlorideSee E625000
• Erlotonid HCl

Erlotinib Hydrochloride

CAS: 183319-69-9

Fórmula: C₂₂H₂₃N₃O₄·HCl

Pureza: >98.0%(HPLC)(T)

Cor e Forma: White to Light yellow powder to crystal

Peso molecular: 429.90

Ref: 3B-E1404

Erlotinib Hydrochloride

CAS: 183319-69-9

Drugs containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure

Fórmula: C₂₂H₂₃N₃O₄·HCl

Cor e Forma: Pale Yellow Powder

Peso molecular: 429.14553

Ref: 45-1241608

Erlotinib Hydrochloride Salt

CAS: 183319-69-9

Erlotinib Hydrochloride Salt

Fórmula: C₂₂H₂₃N₃O₄·ClH

Pureza: By hplc: 99.9% by area (Typical Value in Batch COA)

Cor e Forma: Off-white Solid-Powder

Peso molecular: 429.89665

Ref: 54-BIFK0020

Erlotinib hydrochloride

CAS: 183319-69-9

Erlotinib hydrochloride (NSC 718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.

Fórmula: C₂₂H₂₄ClN₃O₄

Pureza: 99.78% - 99.97%

Cor e Forma: Solid

Peso molecular: 429.897

Ref: TM-T0373L

Erlotinib hydrochloride

CAS: 183319-69-9

Erlotinib hydrochloride

Fórmula: C₂₂H₂₃N₃O₄·HCl

Pureza: ≥98%

Peso molecular: 429.9

Ref: 54-BUP17066

Erlotinib hydrochloride

CAS: 183319-69-9

Fórmula: C₂₂H₂₃ClN₃O₄

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 429.8967

Ref: IN-DA0027I4

Erlotinib hydrochloride

CAS: 183319-69-9

Fórmula: C₂₂H₂₃N₃O₄·HCl

Pureza: ≥ 98.0% (dried basis)

Cor e Forma: White to off-white powder

Peso molecular: 429.90

Ref: 7W-GP3306

Erlotinib HCl

CAS: 183319-69-9

Fórmula: C₂₂H₂₃N₃O₄·HCl

Cor e Forma: White To Off-White Solid

Peso molecular: 393.44 36.46

Ref: 4Z-E-281

Erlotinib Hydrochloride

Produto Controlado

CAS: 183319-69-9

Fórmula: C₂₂H₂₃N₃O₄·ClH

Cor e Forma: Neat

Peso molecular: 429.90

Ref: 86-MM3297.00

Erlotinib Impurity 95

CAS: 183319-69-9

Fórmula: C₁₄H₈ClN₃O₂

Peso molecular: 285.69

Ref: 4Z-E-28118

Erlotinib HCl

CAS: 183319-69-9

N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride

Fórmula: C₂₂H₂₄ClN₃O₄

Pureza: 98%

Peso molecular: 429.9

Ref: IN-DG41395

Erlotinib Hydrochloride

CAS: 183319-69-9

Fórmula: C₂₂H₂₃N₃O₄HCl

Peso molecular: 393.4:36.5

Ref: ST-EA-CP-E17000

Erlotinib Hydrochloride (Tarceva)

Produto Controlado

CAS: 183319-69-9

Applications Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic.
References Moyer, J.D., et al.: Cancer Res., 57, 4838 (1997), Hidalgo, M., et al.: J. Clin. Oncol., 19, 3267 (2001), Perez-Soler, R., et al.: J. Clin. Oncol., 22, 3238 (2004), Blackhall, F.H., et al.: Expert Opin. Pharmacother., 6, 995 (2005),

Fórmula: C₂₂H₂₃N₃O₄·ClH

Cor e Forma: Neat

Peso molecular: 429.9

Ref: TR-E625000

Tarceva (Erlotinib Hydrochloride)

Produto Controlado

CAS: 183319-69-9

Applications Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic.
References Moyer, J.D., et al.: Cancer Res., 57, 4838 (1997), Hidalgo, M., et al.: J. Clin. Oncol., 19, 3267 (2001), Perez-Soler, R., et al.: J. Clin. Oncol., 22, 3238 (2004), Blackhall, F.H., et al.: Expert Opin. Pharmacother., 6, 995 (2005),

Fórmula: C₂₂H₂₃N₃O₄·ClH

Cor e Forma: Neat

Peso molecular: 429.90

Ref: TR-T007500

Erlotinib hydrochloride - Bio-X ™

CAS: 183319-69-9

Erlotinib is a drug that is used to treat human malignancies. It is a type of kinase inhibitor that inhibits the EGFR tyrosine kinase, preventing the activation of downstream signalling pathways. Erlotinib has been shown to be effective in treating squamous cell carcinoma, melanoma, and other types of skin cancer. Additionally, Erlotinib has potential for use as an anti-inflammatory agent in the treatment of psoriasis and ulcerative colitis.

Fórmula: C₂₂H₂₃N₃O₄·HCl

Pureza: Min. 95%

Cor e Forma: Powder

Peso molecular: 429.9 g/mol

Ref: 3D-BE164421

Erlotinib hydrochloride

CAS: 183319-69-9

Ref: BE-RMCE123001

Erlotinib hydrochloride

CAS: 183319-69-9

Fórmula: C₂₂H₂₄ClN₃O₄

Pureza: 98%

Cor e Forma: Solid, Crystalline Powder

Peso molecular: 429.9

Ref: 10-F036497

Erlotinib HCl

CAS: 183319-69-9

Tyrosine kinase inhibitor; affects EGFR receptor; pancreatic cancer treatment

Fórmula: C₂₂H₂₃N₃O₄·HCl

Pureza: Min. 98 Area-%

Cor e Forma: Powder

Peso molecular: 429.9 g/mol

Ref: 3D-FE10803